• Users Online: 286
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
RESEARCH ARTICLE
Year : 2018  |  Volume : 3  |  Issue : 2  |  Page : 71-76

Ranibizumab versus conbercept for wet age-related macular degeneration: Protocol for a prospective cohort study


1 Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, Guizhou Province; Chinese Evidence-based Medicine Centre, Sichuan University, Chengdu, Sichuan Province, China
2 Department of Ophthalmology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou Province, China
3 Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, Guizhou Province, China

Correspondence Address:
Juan Xie
Department of Pharmacy, Guizhou Provincial People’s Hospital, Guiyang, Guizhou Province
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2542-3975.235152

Rights and Permissions

Background and objectives: Conbercept is a novel anti-vascular endothelial growth factor (VEGF) agent for the treatment of wet age-related macular degeneration (wAMD). However, no head-to-head study has compared the effectiveness of conbercept with that of ranibizumab. In this study, we will compare the effectiveness, cost-effectiveness and safety profiles of ranibizumab and conbercept in the treatment of wAMD. Design: This is a single-center, prospective, cohort study. Methods: Patients (≥ 50 years old) diagnosed with wAMD will be allocated to the conbercept or ranibizumab group according to their preference. Following a treat-and-extend protocol, patients will receive intravitreal injections of 0.5 mg conbercept or 0.5 mg ranibizumab every month in the first three injections. Outcome measures: The primary outcome is quality of life, measured with the Chinese version of the Low Vision Quality of Life Questionnaire, from baseline to 48 weeks post-treatment. Secondary outcomes include best corrected visual acuity, central retinal thickness, cost of treatment, intraocular pressure, and adverse events. The follow-up phase will last 1 year. Propensity score matching will be used to deal with differences in baseline between the two groups. A cost-effectiveness analysis will be performed. Discussion: The results of this study will provide clinicians with a rational basis for choosing the most effective treatment for wAMD patients. Ethics and dissemination: This study has been approved by the Medical Ethics Committee of Guizhou Provincial People’s Hospital (approval number: 2017113). Patient recruitment was initiated in November 2017. Analysis of primary outcome measures will be completed in October 2020, and the study will be finished in October 2021. Dissemination plans include presentations at scientific conferences and publication in scientific journals. Trial registration: This study was registered in the Chinese Clinical Trial Registry with registration number of ChiCRT-OPC-17013023, protocol version: 2.0.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1031    
    Printed22    
    Emailed0    
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal